- asthma weed
- Indian pink
- Indian tobacco
- vomit weed
- <em>Lobelia berlandieri</em>
- <em>Lobelia cardinalis</em>
For Patients & Caregivers
Bottom Line: Current evidence shows that lobelia is not effective for smoking cessation, asthma, or any other medical condition.
The active compound in lobelia is lobeline. Lobeline has a similar activity in the body to nicotine, which explains its common use as an aid in smoking cessation. Like nicotine, lobelia stimulates the central nervous system (CNS), dilates the lung passageways, and increases respiration rate. However, at higher doses, lobelia has the opposite effect and causes CNS depression and reduced breathing rate. In experiments with rats and mice, lobeline increased the release of stimulatory neurotransmitters (dopamine and norepinephrine) from specific parts of the brain, but it is still unclear what significance this has in the human body. Strangely, lobeline can have both additive and antagonistic effects when used at the same time as nicotine.
- To treat asthma
Although lobelia is thought to dilate the bronchial tubes, human data are lacking.
- To treat depression
Lobelia causes release of excitatory neurotransmitters in the brains of research animals. Human studies are needed.
- To relieve symptoms from drug withdrawal
No scientific evidence supports this use.
- To induce vomiting
There is no research to back this claim.
- To reduce inflammation
No scientific evidence supports this use.
- To help with smoking cessation
A review of 16 clinical trials concluded that this herb is not effective for smoking cessation.
A systematic review of 16 separate clinical trials was performed to determine the usefulness of lobeline for smoking cessation. All of the clinical trials had flaws in their design, and none followed patients for more than two weeks in order to evaluate the long-term safety and effectiveness of lobeline. The reviewers concluded that there is no evidence to support the hypothesis that lobelia is effective for smoking cessation.
For Healthcare Professionals
Derived from the aerial parts of the plant. Patients use lobelia for smoking cessation and to treat asthma and depression. The piperidine alkaloids are thought responsible for lobelia’s activity. In vitro and animal studies show that lobeline crosses the blood-brain barrier, has activity similar to that of nicotine, and stimulates the release of dopamine and norepinephrine (5). At low doses lobelia has stimulant effects, but higher doses result in CNS depression (10).
Lobeline, a piperidine alkaloid, was shown to reverse multidrug resistance of tumor cells to doxorubicin (16); reduce alcohol consumption (17) and exert antidepressant effects (19) in mice.
Clinical studies of lobelia do not support its use for smoking cessation (15)(18)(20).
Lobelia has central stimulant activity, dilates bronchioles, and increases respiration rate at low doses, but higher doses cause CNS and respiratory depression (10). In rat and mouse models lobeline increases dopamine release from striatal synaptosomes, increases norepinephrine release from the hippocampus (5), and binds extensively to nicotinic receptors both centrally and peripherally (4). In vitro, lobeline redistributes dopamine pools in presynaptic vesicles and antagonizes their release following amphetamine stimulation. Lobeline can have both antagonistic and synergistic effects when combined with nicotine and does not induce receptor up-regulation as seen with nicotine (10). Intravenous administration of approximately 12 mcg/kg lobeline to healthy human subjects resulted in cough, apnea, prolonged inspiration and expiratory pause, the feeling of choking, and pressure in the throat and chest (9). Animal studies suggest that beta-amyrin palmitate stimulates the release of norepinephrine in the brain, possibly leading to an antidepressant effect (1).
Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev. 2012 Feb 15;2:CD000124.
This review was conducted to determine the effects of lobeline on long-term smoking cessation. The Cochrane Tobacco Addiction trials register was searched for randomized trials with at least a six-month follow-up period. The authors did not identify any trials that met the inclusion criteria. A single large clinical trial failed to find any effects of lobeline on short-term abstinence.
There is no evidence from long-term studies to support use of lobeline for smoking cessation. Data from short-term trials do not suggest any benefits.